Abstract:

Objective To explore the safety of neoadjuvant chemotherapy for advanced （stage Ⅲ） gastric cancer and its recent effi-cacy.　Methods A total of 138 patients with locally advanced gastric cancer （stage Ⅲ） confirmed by Affiliated Tumor Hospital of Guangxi Medical University from March 2012 to March 2016 were divided into trial group（n=50） and control group（n=88）. Patients in the trial group underwent both neoadjuvant chemotherapy and surgery，control patients underwent surgery and adjuvant chemotherapy. Surgical complications and recent efficacy were compared between the two groups. Results The median survival time was 36.9 months in trial group and 30.9 months in control group （P=0.317）. The trial group showed lower recurrence rates of 12 months （34.0% vs 52.3%，P=0.038），and higher R0 resection rate（84.0% vs 68.2%，P=0.042）. The two groups experienced similar major complications （P>0.05）. The trial group showed more intraoperative blood transfusion， more intraoperative blood loss， longer operation time and more lymph node metastasis（P<0.05）， and there was no difference between patients who underwent combined organ resection（P>0.05）. Conclusion Neoadjuvant chemotherapy can improve the R0 resection rate，reduce recurrence rate of advanced gastric cancer，and is not a risk factor for surgical complications.

Key words: Gastric neoplasms, Advanced gastric cancer, Neoadjuvant chemotherapy, Surgical complications, Recent efficacy